90
Participants
Start Date
December 6, 2012
Primary Completion Date
August 7, 2017
Study Completion Date
July 31, 2027
Tenofovir DF
"* Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300 mg."
TDF Placebo
"* Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.~* Participants weighing \< 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
National Taiwan University Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Kyungpook National University, Daegu
Cincinnati Children's Hospital Medical Center, Cincinnati
Pusan National University Yangsan Hospital, Yangsan
Texas Children's Hospital, Houston
Children's Hospital Colorado, Aurora
Phoenix Children's Hospital, Phoenix
University of California, San Francisco, San Francisco
Victor Babes Clinical Hospital of Infectious Diseases and Pneumophtisology, Craiova
M.V. Hospital and Research Centre 314/30 Mirza Mandi Chowk, Lucknow
SMS Medical College and Hospital, Jaipur
Colors Children Hospital, Nagpur
St. John Hospital & Medical Center, Bangalore
Nirmal Hospital Private Limited, Surat
Medanta -The Medicity, Gurgaon
Grigore Alexandrescu Emergency Clinical Hospital for Children, Bucharest
Fundeni Clinical Institute - Constantinesco, Bucharest
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Severance Children's Hospital, Seoul
Lead Sponsor
Gilead Sciences
INDUSTRY